New Huntington's drug candidate SAGE-718 enters first human safety tests

NCT ID NCT03787758

Completed Disease control Sponsor: Supernus Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-stage trial tested the safety and tolerability of an experimental drug called SAGE-718 in 6 healthy adults and a small group of people with Huntington's disease. Researchers looked for side effects and measured how the drug moves through the body. The goal was to see if the drug is safe enough to study further, not to test if it works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SAGE-718
What this could lead to: If this early trial shows the drug is safe, it could pave the way for larger studies testing whether SAGE-718 can help control Huntington's disease symptoms.
What could go wrong: This is a very small, early-stage trial focused on safety, not effectiveness. The drug may not work for Huntington's or could have side effects. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HUNTINGTON DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Huntington disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HUNTINGTON DISEASE

Contacts and locations

Locations

Sage Investigational Site

Long Beach, California, 90806, United States
Sage Investigational Site

Marlton, New Jersey, 08053, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.